ACTEMRA 162 MG / 0.9 ML
TOCILIZUMAB : 162 MG / 0.9 ML · DIN 02424770 · HOFFMANN-LA ROCHE LIMITED
Health Canada status: MARKETED
What is ACTEMRA?
ACTEMRA 162 MG / 0.9 ML contains TOCILIZUMAB : 162 MG / 0.9 ML. It is listed in the Health Canada Drug Product Database under DIN 02424770, held by HOFFMANN-LA ROCHE LIMITED, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 30-May-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ACTEMRA used for?
ACTEMRA (tocilizumab) is indicated for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis; for the treatment of giant cell arteritis (GCA) in adult patients; for the treatment of signs and symptoms of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older who have responded inadequately to previous therapy with DMARDs; for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older, who have responded inadequately to previous therapy with one or more non-steroidal anti-inflammatory drugs and systemic corticosteroids; for the treatment of patients with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS); and for the treatment of hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids, and require supplemental oxygen, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02424770 |
|---|---|
| Brand name | ACTEMRA |
| Generic / active ingredient | TOCILIZUMAB : 162 MG / 0.9 ML |
| Manufacturer | HOFFMANN-LA ROCHE LIMITED |
| Strength | 162 MG / 0.9 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | L04AC07 TOCILIZUMAB |
| AHFS class | 90:24.20.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 30-May-2014 |
| Original market date | 2014-05-30 00:00:00 |
How is it stored and handled?
It can be stored for 24 hours at 30 °C and up to 2 weeks in a refrigerator at 2 °C - 8°C.
How is it supplied?
tocilizumab for injection (20 mg/mL) vials, tocilizumab injection (162 mg/ 0.9 mL) pre-filled syringe and Autoinjector
What can be used instead?
Other Canadian products sharing ATC code L04AC07 TOCILIZUMAB. 10 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACTEMRA | 162 MG / 0.9 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02483327 |
| ACTEMRA | 200 MG / 10 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02350106 |
| ACTEMRA | 400 MG / 20 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02350114 |
| ACTEMRA | 80 MG / 4 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02350092 |
| TYENNE | 162 MG / 0.9 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02552493 |
| TYENNE | 162 MG / 0.9 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02552485 |
| TYENNE | 200 MG / 10 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02552469 |
| TYENNE | 400 MG / 20 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02552477 |
| TYENNE | 80 MG / 4 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02552450 |
Who else supplies TOCILIZUMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TOCILIZUMAB appears in 184 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.